Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM, PhRMA Renew Rivalry In Hatch-Waxman Public Comments

Executive Summary

Generic association advocates enforcement action against companies that use REMS to block generics while PhRMA disputes claims of REMS abuse and citizen petition delay tactics.

You may also be interested in...



Pay-For-Delay, REMS Reform Legislation Making (Slow) Progress In House

CREATES Act gets a hearing, but Judiciary committee members spend much of their time asking questions about basic concepts of FDA review.

Brand 'Evergreening' Piques FDA Interest, But Solutions Remain Elusive

Agency eager to hear suggestions on the subject, also known as product hopping, but even reform advocates were cautious of stifling meaningful reformulations of products.

Brands Push Back Against REMS Reform, Call Problem Small With Burdensome Fixes

BIO cautioned that its members may have difficulties meeting the purchase orders of product for generic sponsors, while PhRMA contended legislation is not necessary.

Related Content

Topics

UsernamePublicRestriction

Register

GB002057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel